Literature DB >> 25032812

Pulmonary vascular complications of hereditary haemorrhagic telangiectasia.

Sebastian Circo1, James R Gossage.   

Abstract

PURPOSE OF REVIEW: The purpose of this study is to present the latest advances and recommendations in the diagnosis and treatment of pulmonary vascular complications associated with hereditary haemorrhagic telangiectasia (HHT): pulmonary arteriovenous malformations (PAVMs), pulmonary arterial hypertension (PAH), pulmonary hypertension associated with high output cardiac failure or liver vascular malformations, haemoptysis, haemothorax and thromboembolic disease. RECENT
FINDINGS: Transthoracic contrast echocardiography has been validated as a screening tool for PAVM in patients with suspected HHT. Advancements in genetic testing support its use in family members at risk as a cost-effective measure. Therapy with bevacizumab in patients with high output cardiac failure and severe liver AVMs showed promising results. PAH tends to be more aggressive in HHT type 2 patients.
SUMMARY: Patients suffering from this elusive disease should be referred to HHT specialized centres to ensure a standardized and timely approach to diagnosis and management.

Entities:  

Mesh:

Year:  2014        PMID: 25032812     DOI: 10.1097/MCP.0000000000000076

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  9 in total

Review 1.  Pulmonary arteriovenous malformations: diagnosis.

Authors:  Sachin S Saboo; Murthy Chamarthy; Sanjeev Bhalla; Harold Park; Patrick Sutphin; Fernando Kay; John Battaile; Sanjeeva P Kalva
Journal:  Cardiovasc Diagn Ther       Date:  2018-06

Review 2.  Pulmonary arteriovenous malformations.

Authors:  Claire L Shovlin
Journal:  Am J Respir Crit Care Med       Date:  2014-12-01       Impact factor: 21.405

3.  Pulmonary hypertension in hereditary haemorrhagic telangiectasia.

Authors:  Veronique Mm Vorselaars; Sebastiaan Velthuis; Repke J Snijder; Jan Albert Vos; Johannes J Mager; Martijn C Post
Journal:  World J Cardiol       Date:  2015-05-26

Review 4.  Cardiac and Hemodynamic Manifestations of Hereditary Hemorrhagic Telangiectasia.

Authors:  Ahmed Farhan; Muhammad A Latif; Anum Minhas; Clifford R Weiss
Journal:  Int J Angiol       Date:  2022-07-09

5.  Neurovascular Complications and Pulmonary Arteriovenous Malformation Feeding Artery Size.

Authors:  Theodora Ananiadis; Marie E Faughnan; Dewi Clark; Vikram Prabhudesai; Helen Kim; Michael T Lawton; Nicholas T Vozoris
Journal:  Ann Am Thorac Soc       Date:  2022-08

6.  Restless Leg Syndrome Is Underdiagnosed in Hereditary Hemorrhagic Telangiectasia-Results of an Online Survey.

Authors:  Freya Droege; Andreas Stang; Kruthika Thangavelu; Carolin Lueb; Stephan Lang; Michael Xydakis; Urban Geisthoff
Journal:  J Clin Med       Date:  2021-05-06       Impact factor: 4.241

7.  Reproducibility of right-to-left shunt quantification using transthoracic contrast echocardiography in hereditary haemorrhagic telangiectasia.

Authors:  V M M Vorselaars; S Velthuis; M P Huitema; A E Hosman; C J J Westermann; R J Snijder; J J Mager; M C Post
Journal:  Neth Heart J       Date:  2018-04       Impact factor: 2.380

8.  Pulmonary arteriovenous malformation exhibiting recanalization >10 years after coil embolization: Two case reports.

Authors:  Shun Takao; Takeshi Masuda; Takahiro Yamada; Kakuhiro Yamaguchi; Shinjiro Sakamoto; Hayato Matsushima; Yasushi Horimasu; Taku Nakashima; Shintaro Miyamoto; Hiroshi Iwamoto; Kazunori Fujitaka; Hironobu Hamada; Noboru Hattori
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

Review 9.  Pulmonary Vascular Complications in Hereditary Hemorrhagic Telangiectasia and the Underlying Pathophysiology.

Authors:  Sala Bofarid; Anna E Hosman; Johannes J Mager; Repke J Snijder; Marco C Post
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.